María Luisa Fontalva

Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center

Mario Balsa, Francesc Feliu Torrent, Diana Pérez, Alejandro Ruiz et autres

Introduction: Chordoma is a rare malignant tumor originating in the notochord characterized by slow progression but frequent recurrences. Systemic treatment for this condition is not well defined. This study aimed to describe real-world clinical practice patterns of systemic therapy and its outcomes …

es (code pays fourni par la source)

2747eP Efficacy of immunotherapy and tyrosine kinase inhibitors (TKIs) in chordoma in an EURACAN member centre: A 20-year retrospective analysis

M. Balsa Pena, F. Torrent, Diana Pérez Sidelnikova, A. Ruiz Castellón et autres

es (code pays fourni par la source)

A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone

Carolina de la Calva, Manuel Rubio Angulo, Paula González‐Rojo, Ana Maestre Peiró et autres

Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spain affiliated …

es (code pays fourni par la source)

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?

Carolina de la Calva, Manuel Rubio Angulo, Paula González‐Rojo, Ana María Peiró et autres

BACKGROUND: Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment. AIMS: To …

es (code pays fourni par la source)